Physician profile
Thomas E Trouillot
NPI 1902850811
$6,724.56
in general payments reported to CMS, 2019-2025
33 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $195 · 2021: $267 · 2022: $1,189 · 2023: $1,868 · 2024: $1,184 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,205 · Education: $19.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,204.99 |
| Education | $19.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.93 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $846.82 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $750.03 | 2019-2025 | |
| Pfizer INC. | $523.65 | 2019-2024 | |
| Janssen Biotech, INC. | $507.00 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $411.32 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $257.98 | 2023 | Cre Pro, Resolution 360 Clip |
| Genzyme Corporation | $226.99 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $195.48 | 2023-2025 | Dupixent |
| Micro-Tech Endoscopy USA, INC. | $185.64 | 2024 | Hemostasis Clips, Snares |
| Organon LLC | $138.73 | 2022-2025 | Hadlima, Renflexis |
| Braintree Laboratories, INC. | $123.22 | 2019-2025 | Suflave |
| Intercept Pharmaceuticals, INC. | $113.78 | 2019-2025 | |
| Lilly USA, LLC | $106.38 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $99.09 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.48 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $69.65 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $69.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $61.19 | 2019 | |
| Ferring Pharmaceuticals INC. | $53.43 | 2021-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $51.46 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $43.27 | 2022 | |
| Aimmune Therapeutics, INC. | $43.03 | 2024-2025 | Zenpep |
| Amgen INC. | $34.88 | 2022-2023 | Amjevita, Avsola |
| Daiichi Sankyo INC. | $30.09 | 2023 | Injectafer |
| Fresenius Kabi USA, LLC | $26.72 | 2023 | Idacio |
| Medtronic, INC. | $25.20 | 2025 | Pillcam |
| Ironwood Pharmaceuticals, INC | $20.00 | 2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.85 | 2022 | |
| Sanofi US Services INC. | $15.32 | 2024 | |
| Novo Nordisk INC | $14.11 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $13.83 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,517.92 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Trouillot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.